Navigation Links
US FDA Grants Pediatric Exclusivity for UCB's Keppra(R)
Date:6/6/2008

43.1% of levetiracetam-treated patients experiencing at least a 50% reduction in seizure frequency during the evaluation period (five days) compared with 19.6% of placebo-treated patients (p=0.013). Levetiracetam was generally well-tolerated in this pediatric population. The most commonly reported adverse events that occurred more frequently in the treatment group were somnolence (13.3% vs. 1.8% for placebo) and irritability (11.7% vs. 0 for placebo). The incidence of other adverse events was similar in both groups.

In October 2007, UCB announced that it had reached an agreement to settle pending patent infringement lawsuits in the US. Under the terms of the settlement agreement with Mylan, and subject to its receiving FDA approval, Mylan will be allowed to sell its generic levetiracetam tablets effective November 1, 2008, in advance of the expiry of UCB's market exclusivity on January 14, 2009.

About Epilepsy: Epilepsy is a chronic neurological disorder affecting 40 million people worldwide including 2.5 million people in the US. It is caused by abnormal, excessive electrical discharges of the nerve cells or neurons in the brain. Epilepsy is characterized by a tendency to have recurrent seizures and defined by two or more unprovoked seizures. There are many different seizure types and epileptic syndromes and effective classification guides treatment and prognosis. Between 70-80% of individuals are successfully treated with one of the more than 20 antiepileptic drugs now available. However, 20-30% of patients have either intractable or uncontrolled seizures or significant adverse side effects secondary to medication highlighting the ongoing need for the development of new antiepileptic drugs.

About Keppra(R) in the US: Keppra(R) (levetiracetam) tablets were first approved by the FDA in 1999 as adjunctive therapy in the treatment of partial onset seizures in adults with epilepsy. Since 1999, Keppra(R) has received several supplemental indications
'/>"/>

SOURCE UCB
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Xceed Molecular Grants Gen-Probe License to Xceeds Flow-Thru Chip(R) Technology for Multiplex Molecular Diagnostics
2. CV Therapeutics Reports Option Grants Under Nasdaq Marketplace Rule 4350
3. Intellect Neurosciences, Inc. Grants License for Certain Patents and Patent Applications to Wyeth and Elan Pharma International Ltd.
4. Lentigen Corporation Receives Four Research Grants From the National Institutes of Health
5. Susan G. Komen for the Cure(R) Announces Largest Grants Slate Ever: $100 Million to Speed Delivery of Breast Cancer Discoveries, Cures
6. European Union, State of Brandenburg, Award Grants to Alcat Europe, GmbH
7. FDA Grants Market Clearance to Aerocrine Inc.s NIOX MINO(R): a New Hand-Held Device to Measure Airway Inflammation in Asthma
8. CV Therapeutics Reports Option Grants Under Nasdaq Marketplace Rule 4350
9. United States Patent Office Grants CryoCors Request for Patent Interference
10. Christopher and Dana Reeve Foundation Awards Nearly $2 Million in Individual Research Grants
11. FDA Grants Priority Review for Schering-Ploughs Peginterferon Alfa-2b for the Adjuvant Treatment of Patients With Stage III Melanoma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/13/2014)... The “Global Synthetic Biology Market ... threats, opportunities, and challenges. , The global synthetic ... namely, Thermo Fisher Scientific, Inc. (U.S.), DuPont (U.S.), ... accounted for approximately ~65% of the total synthetic ... for This Report @ http://www.marketsandmarkets.com/Market-Reports/synthetic-biology-market-889.html , ...
(Date:12/13/2014)... , Dec. 12, 2014  Vermillion, Inc. (NasdaqCM: VRML), a ... the appointments of Veronica G. H. Jordan , ... Company,s Board of Directors, bringing the total number of ... Jim LaFrance , Chairman, President, and ... pleased to announce the appointments of Veronica and David ...
(Date:12/13/2014)... RARITAN, N.J. and SAN ANTONIO ... Development, LLC (Janssen) today announced the presentation of data ... the Phase 3 EPO-ANE-3010 study evaluating epoetin alfa plus ... treat anemia in patients with metastatic breast cancer receiving ... primary objective, which was to rule out a 15 ...
(Date:12/12/2014)... Pittsburgh, PA (PRWEB) December 11, 2014 ... 2015 Technical Program that includes over 2,000 ... awards, and posters. This year’s program covers ... not limited to, biotechnology, biomedical, drug discovery, environmental, ... nanotechnology, polymers/plastics, proteomics and water/wastewater. The Technical ...
Breaking Biology Technology:Synthetic Biology Market to HIt $5.6304 Billion by 2018 - New Research Report by MarketsandMakets 2Synthetic Biology Market to HIt $5.6304 Billion by 2018 - New Research Report by MarketsandMakets 3Vermillion Strengthens Board of Directors with Appointments of Veronica Jordan, Ph.D., and David Schreiber 2Vermillion Strengthens Board of Directors with Appointments of Veronica Jordan, Ph.D., and David Schreiber 3Data from the EPO-ANE-3010 Study Evaluating Epoetin Alfa Presented at San Antonio Breast Cancer Symposium 2Data from the EPO-ANE-3010 Study Evaluating Epoetin Alfa Presented at San Antonio Breast Cancer Symposium 3Data from the EPO-ANE-3010 Study Evaluating Epoetin Alfa Presented at San Antonio Breast Cancer Symposium 4Data from the EPO-ANE-3010 Study Evaluating Epoetin Alfa Presented at San Antonio Breast Cancer Symposium 5Data from the EPO-ANE-3010 Study Evaluating Epoetin Alfa Presented at San Antonio Breast Cancer Symposium 6Data from the EPO-ANE-3010 Study Evaluating Epoetin Alfa Presented at San Antonio Breast Cancer Symposium 7Data from the EPO-ANE-3010 Study Evaluating Epoetin Alfa Presented at San Antonio Breast Cancer Symposium 8Data from the EPO-ANE-3010 Study Evaluating Epoetin Alfa Presented at San Antonio Breast Cancer Symposium 9Data from the EPO-ANE-3010 Study Evaluating Epoetin Alfa Presented at San Antonio Breast Cancer Symposium 10Data from the EPO-ANE-3010 Study Evaluating Epoetin Alfa Presented at San Antonio Breast Cancer Symposium 11Data from the EPO-ANE-3010 Study Evaluating Epoetin Alfa Presented at San Antonio Breast Cancer Symposium 12Pittcon Announces a Diverse 2015 Technical Program - Renowned Speakers, Special Symposia and Co-programming 2Pittcon Announces a Diverse 2015 Technical Program - Renowned Speakers, Special Symposia and Co-programming 3
... Company Purchases Two PCT Systems to Help in the Analysis of ... SOUTH EASTON, Mass., Dec. 17 Pressure BioSciences, Inc. ... entered into a collaboration with the J. Craig Venter Institute ("JCVI"), ... MD and La Jolla, CA. As part of the collaboration, ...
... recent customer satisfaction,survey of over 30,000 readers of ADVANCE ... customers as the "Top Of Class" winner for the,microbiology ... ADVANCE chose bioMerieux over other clinical laboratory suppliers,because of ... "quick response time." , ...
... scheduled 16-17 February in Kuala Lumpur, Malaysia, an ... makers have been scheduled. Kicking off the series, ... Pradip Bhar, Chief Executive Officer and Managing Director ... download, this informative interview lends startling insights into ...
Cached Biology Technology:Pressure BioSciences, Inc. and the J. Craig Venter Institute Announce Collaboration Agreement & Purchase of a PCT System 2Pressure BioSciences, Inc. and the J. Craig Venter Institute Announce Collaboration Agreement & Purchase of a PCT System 3Pressure BioSciences, Inc. and the J. Craig Venter Institute Announce Collaboration Agreement & Purchase of a PCT System 4Pressure BioSciences, Inc. and the J. Craig Venter Institute Announce Collaboration Agreement & Purchase of a PCT System 5Laboratory Customers Name bioMerieux 'Top Of Class' for Microbiology 2Jatropha World 2009 Advance Access: Surprisingly Candid Interview Series Examines Biofuel Predictions Compared to Fossil Fuels 2Jatropha World 2009 Advance Access: Surprisingly Candid Interview Series Examines Biofuel Predictions Compared to Fossil Fuels 3Jatropha World 2009 Advance Access: Surprisingly Candid Interview Series Examines Biofuel Predictions Compared to Fossil Fuels 4
(Date:12/11/2014)... , Dec. 10, 2014  That blood pressure plays ... a while. Hypertension – the medical term for high blood ... early 1800s, and the inflatable cuff that,s used in measuring ... however, mean there,s nothing new about hypertension, its triggers and ... beliefs about the condition and the best ways to treat ...
(Date:12/10/2014)... , Dec. 9, 2014  Valencell, a leader ... is seeing a staggering demand from its licensees for ... Company revealed, is not solely coming from fitness and ... well. "A wearable is only as useful ... accuracy is the ultimate driver in long-term mass consumer ...
(Date:12/10/2014)... --Research and Markets ( http://www.researchandmarkets.com/research/xclcvw/biometrics_market ) ... Market in Japan 2014-2018" report to their ... The integration of biometrics and smart ... upgradation of the driver,s license is one of ... the aforementioned projects, biometrics is being used as ...
Breaking Biology News(10 mins):Research points to need for new approaches to treatment of high blood pressure 2Research points to need for new approaches to treatment of high blood pressure 3Research points to need for new approaches to treatment of high blood pressure 4Wearable Technology Products Demand Highly Accurate Biometric Technology 2Biometrics Market in Japan 2014-2018: Key Vendors are DDS, Fujitsu, Hitachi and NEC 2
... (January 28, 2013)A popular dog treat could be adding ... contaminated by bacteria, according to a study published this ... Medicine at Tufts University and the University of Guelph. ... stick." The American and Canadian researchers analyzed the caloric ...
... CORVALLIS, Ore. Dairy cows that are fed flaxseed produce ... State University. Their milk contained more omega-3 fatty acids ... in saturated fat can increase cholesterol and cause heart disease, ... may reduce the risk of heart disease, studies have shown. ...
... in German . , The detector ... has a very low error rate. The results have ... Ultrafast, efficient, and reliable single-photon detectors are among the ... have not yet reached maturity for practical application. Physicist ...
Cached Biology News:Misconceptions about a popular pet treat 2Misconceptions about a popular pet treat 3Cows fed flaxseed produce more nutritious dairy products 2Quantum communication: Each photon counts 2
...
... Characteristics:, Antibody Binding: High, 400 ng ... volume) , Binding Interaction: Hydrophobic/Ionic , Performance ... (bottom): Flat , Maximum Well Volume: 360 ... tray ,Features, Special optically clear ...
...
...
Biology Products: